Open AccessNew approaches to pharmacogenetics of drug-induced hyperprolactinemia in patients with schizophrenia
Author(s) -
Светлана Иванова
Publication year - 2019
Publication title -
obozrenie psihiatrii i medicinskoj psihologii im. v.m. behtereva/obozrenie psihiatrii i medicinskoj psihologii imeni v.m. behtereva
Language(s) - English
Resource type - Journals
eISSN - 2713-055X
pISSN - 2313-7053
DOI - 10.31363/2313-7053-2019-4-1-21-23
Subject(s) - pharmacogenetics , schizophrenia (object oriented programming) , genotyping , antipsychotic , tph2 , dopamine , medicine , drug , gene , genetics , bioinformatics , pharmacology , psychiatry , genotype , biology , serotonin , serotonergic , receptor
The pathogenesis of the development of drug-induced disorders while taking antipsychotic drugs is not well understood. The aim of the work is to study polymorphic variants of the multidrug resistance protein gene and genes encoding the metabolism and synthesis of dopamine and serotonin enzymes in antipsychotic-induced hyperprolactinemia in schizophrenia patients. As a result of a comprehensive study of 446 patients with schizophrenia and genotyping of 25 polymorphic variants of the MDR1, COMT, MAO-A, MAO-B, TPH1 and TPH2 genes, associations of polymorphisms rs1045642, rs2032582, rs4148739 (MDR1), rs6323 (MAO-А), rs1799836 (MAO-B) were revealed with the development of hyperprolactinemia. Further research is needed to develop personalized approaches to therapy.